Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Almotriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 4/20 | 0.65 |
| ▸ | HTR1B known ✓ | P28222 | 4/20 | 0.65 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 11/20 | 0.65 |
| ▸ | HTR7 | P34969 | 2/20 | 0.65 |
| ▸ | HTR2C | P28335 | 2/20 | 0.65 |
| ▸ | HTR1E | P28566 | 1/20 | 0.65 |
| ▸ | HTR3A | P46098 | 1/20 | 0.65 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Almotriptan SCHEMBL29396422 | 1.00 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL3273179 | 1.00 | HTR1A (1.00) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| SCHEMBL1437 | 0.99 | HTR1A (0.98) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL2166 | 0.99 | HTR1A (0.98) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Hydrochloric Acid SCHEMBL2312 | 0.98 | HTR1A (0.96) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL5042399 | 0.98 | HTR1A (0.96) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL1774275 | 0.95 | HTR1A (0.90) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL2761861 | 0.93 | HTR1A (0.86) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL6444414 | 0.93 | HTR1A (0.86) | HTR1AHTR2AHTR2BLMNAADRA2B | |
| Almotriptan SCHEMBL221132 | 0.92 | HTR1A (0.85) | HTR1AHTR2AHTR2BLMNAADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8445 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4734974-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | Mabewo Phytopharm AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-4681714-A2 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | MapLight Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-6060499-A | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs | POZEN, INC. (US) | 2000-05-09 | — | — | US | claimed |
| JP-2000505090-A | — | — | 2000-04-25 | — | — | JP | claimed |
| WO-2000006161-A1 | PREVENTION OF MIGRAINE RECURRENCE | PFIZER LIMITED (GB) | 2000-02-10 | — | — | WO | claimed |
| EP-0969842-A1 | PHARMACEUTICAL COMPOSITION | R.P. Scherer Limited (GB) | 2000-01-12 | — | — | EP | claimed |
| WO-1999064044-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| CN-1225018-A | Inclusion complex containing indole selective serotonin agonist | FARMARC NEDERLAND BV (NL) | 1999-08-04 | — | — | CN | claimed |
| EP-0605697-B1 | INDOL DERIVATIVES FOR THE TREATMENT OF MIGRAINE | ALMIRALL PRODESFARMA SA (ES) | 1999-03-03 | — | — | EP | claimed |
| WO-1998042344-A1 | PHARMACEUTICAL COMPOSITION | R. P. SCHERER LIMITED (GB) | 1998-10-01 | — | — | WO | claimed |
| WO-1998002186-A1 | INCLUSION COMPLEX CONTAINING INDOLE SELECTIVE SEROTONIN AGONIST | FARMARC NEDERLAND B.V. (NL) | 1998-01-22 | — | — | WO | claimed |
| US-5565447-A | ALMOTRIPTAN MALATE; TREATING HEADACHES, MOVEMENT DISORDERS, DEPRESSION, ANXIETY | LABORATORIOS ALMIRALL S.A. (ES) | 1996-10-15 | — | — | US | claimed |